{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:37:04Z","timestamp":1789043824295,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Anti-SSA antibodies target two unrelated proteins, Ro52 (E3 ligase) and Ro60 (RNA binding protein). Previous studies indicate that anti-Ro52 antibodies are frequently associated with various myositis-specific autoantibodies (MSAs)\u2013including anti-tRNA synthetase antibodies\u2014and that the coexistence of MSAs and anti-Ro52 antibodies may portend worse clinical outcomes. Although not well-described in the setting of myositis, work from our animal model of HRS (histidyl-tRNA synthetase)-induced myositis suggests that anti-Ro60 antibodies may also be linked to specific MSAs such as anti-HRS\/Jo-1. We therefore aimed to demonstrate the prevalence and clinical characteristics of Ro52 and Ro60 antibody positivity in patients possessing Jo-1 antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>To establish the immunological link between anti-synthetase, anti-Ro52, and anti-Ro60 antibodies, we evaluated the relative titers of these antibodies in blood and bronchoalveolar lavage fluid (BALF) of mice following immunization with HRS\/Jo-1. In parallel, we used ELISA-based approaches to assess sera from 177 anti-Jo1 antibody-positive patients for the presence of anti-Ro52 and\/or anti-Ro60 antibodies. We then determined statistical associations between co-existing anti-Jo-1, anti-Ro52, and\/or anti-Ro60 antibodies and clinical manifestations associated with the anti-synthetase syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mice immunized with HRS had higher levels of anti-Ro52 and anti-Ro60 antibodies in serum and BALF than PBS-immunized mice. In 177 anti-Jo-1 antibody-positive patients, the prevalence of anti-Ro52 and anti-Ro60 antibodies was 36% and 15%, respectively. The frequency of dry eye\/dry mouth, interstitial pneumonia, and pulmonary events over time differed between patients with various combinations of anti-Ro52 and anti-Ro60 antibodies. While anti-Ro52 antibodies generally correlated with statistically significant increases in each of these clinical manifestations, the presence of Ro60 antibodies alone was associated with decreased frequency of ILD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Anti-Ro52 and\/or anti-Ro60 antibodies are often co-expressed with anti-Jo1 antibodies, defining clinical subsets with different disease course\/outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1399451","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T05:28:35Z","timestamp":1717478915000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical features associated with the presence of anti-Ro52 and anti-Ro60 antibodies in Jo-1 antibody-positive anti-synthetase syndrome"],"prefix":"10.3389","volume":"15","author":[{"given":"Koichi","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Poland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Reay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana P.","family":"Ascherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann rheumatic diseases"},{"key":"B2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13317-014-0060-4","article-title":"Myositis autoantibodies and clinical phenotypes","volume":"5","author":"Ghirardello","year":"2014","journal-title":"Autoimmun Highlights"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.022","article-title":"Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review","volume":"13","author":"Mahler","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann rheumatic diseases"},{"key":"B7","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/j.jaut.2021.102724","article-title":"Anti-Ro60 and anti-Ro52\/TRIM21: Two distinct autoantibodies in systemic autoimmune diseases","volume":"124","author":"Lee","year":"2021","journal-title":"J Autoimmunity"},{"key":"B8","article-title":"Anti-Ro52 and\/or anti-Ro60 immune reactivity: autoantibody and disease associations","volume":"38","author":"Zampeli","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/RHU.0b013e3181b0e910","article-title":"Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience","volume":"15","author":"Mileti","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06404-8","article-title":"Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China","volume":"42","author":"Wang","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/2397198320902667","article-title":"Antisynthetase syndrome: a distinct disease spectrum","volume":"5","author":"Huang","year":"2020","journal-title":"J Scleroderma Related Disord"},{"key":"B12","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis rheumatism"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3718-1","article-title":"A review of the role and clinical utility of anti-Ro52\/TRIM21 in systemic autoimmunity","volume":"37","author":"Lee","year":"2017","journal-title":"Rheumatol Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203070","article-title":"Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositis","volume":"191","author":"Fernandez","year":"2013","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1238221","article-title":"Antigen-driven T cell-macrophage interactions mediate the interface between innate and adaptive immunity in histidyl-tRNA synthetase-induced myositis","volume":"14","author":"Reay","year":"2023","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/art.30113","article-title":"Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis","volume":"63","author":"Soejima","year":"2011","journal-title":"Arthritis Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2007.07.005","article-title":"Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation","volume":"29","author":"Katsumata","year":"2007","journal-title":"J Autoimmun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.30113","article-title":"Role of innate immunity in a murine model of histidyl\u2013transfer RNA synthetase (Jo-1)\u2013mediated myositis","volume":"63","author":"Soejima","year":"2011","journal-title":"Arthritis Rheumatism"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203070","article-title":"Functional redundancy of myD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase\u2013induced myositis","volume":"191","author":"Fernandez","year":"2013","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-022-02085-8","article-title":"Increased susceptibility to organic dust exposure-induced inflammatory lung disease with enhanced rheumatoid arthritis-associated autoantigen expression in HLA-DR4 transgenic mice","volume":"23","author":"Poole","year":"2022","journal-title":"Respir Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5334.2002","article-title":"Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice","volume":"277","author":"Hautamaki","year":"1997","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.1093\/rheumatology\/keab236","article-title":"Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy","volume":"60","author":"Rockette-Wagner","year":"2021","journal-title":"Rheumatology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheumatism"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis rheumatism"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis rheumatism"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheumatism"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2730-z","article-title":"Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis","volume":"33","author":"Aguila","year":"2014","journal-title":"Clin Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B30","first-page":"554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume-title":"Ann Rheum Dis","author":"Vitali","year":"2002"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21591","article-title":"American College of Rheumatology classification criteria for Sj\u00f6gren\u2019s syndrome: a data-driven, expert consensus approach in the Sj\u00f6gren\u2019s International Collaborative Clinical Alliance cohort","volume":"64","author":"Shiboski","year":"2012","journal-title":"Arthritis Care Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew426","article-title":"Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2012.01.014","article-title":"The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review","volume":"39","author":"Oke","year":"2012","journal-title":"J Autoimmun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/10409238.2019.1608902","article-title":"Ro60 and Y RNAs: structure, functions, and roles in autoimmunity","volume":"54","author":"Boccitto","year":"2019","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00444","article-title":"Diagnostic utility of separate anti-Ro60 and anti-Ro52\/TRIM21 antibody detection in autoimmune diseases","volume":"10","author":"Robbins","year":"2019","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1046\/j.1365-2249.1997.4081308.x","article-title":"Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy","volume":"109","author":"Rutjes","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"103013","DOI":"10.1016\/j.autrev.2021.103013","article-title":"An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management","volume":"21","author":"Decker","year":"2022","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1399451\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:08:28Z","timestamp":1721383708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1399451\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2024.1399451"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1399451","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"article-number":"1399451"}}